What question did this study set out to answer?

Synthesize emerging therapeutic paradigms, ongoing clinical trials, and regulatory endpoints aimed at eliminating circulating tumor DNA-defined minimal residual disease in early-stage colorectal cancer.

July 1, 2026Cancer Pathogenesis and TherapyOpen Access

Targeting minimal residual disease (MRD) in colorectal cancer: Therapeutic strategies, clinical trials, and the path toward molecular cure

View Full Paper

Ask AI

Bookmark

Authors

YKYusuf S. KhanUniversity of Ha'il AFAisha FarhanaJouf University HNHatim Adam NagiUniversity of Ha'il

Discussion

Member takes

Implication

Review reveals treatment gaps and emerging therapies for minimal residual disease in colorectal cancer, highlighting the need for novel regimens and surrogate endpoints.

Key Points

Synthesize emerging therapeutic paradigms, ongoing clinical trials, and regulatory endpoints aimed at eliminating circulating tumor DNA-defined minimal residual disease in early-stage colorectal cancer.
Reviewed literature and active clinical trials evaluating adjuvant therapies guided by postoperative circulating tumor DNA (ctDNA) detection.
Assessed trial designs investigating intensified chemotherapy, targeted agents, and novel immunotherapy combinations in microsatellite-stable colorectal cancer.
Analyzed the utility of ctDNA dynamics as a surrogate regulatory endpoint and evaluated implementation hurdles, including global health equity.
Postoperative ctDNA detection reliably identifies patients at high recurrence risk while sparing surgery-cured patients from unnecessary chemotherapy, yet standard adjuvant chemotherapy frequently fails to eradicate this residual disease.
Emerging interventions under active trial investigation include intensified cytotoxic regimens, molecularly targeted therapies, and immunotherapy combinations designed to eliminate treatment-refractory minimal residual disease.
Establishing ctDNA clearance as a validated surrogate endpoint is essential for expediting drug approvals and accelerating clinical translation into improved overall survival.

Cite This Study

Khan et al. (2026) studied this question.

synapsesocial.com/papers/6a6f4b13febe604dd70841f5 https://doi.org/10.1016/j.cpt.2026.07.003

View Full Paper

Ask AI

Bookmark

Implication

Review reveals treatment gaps and emerging therapies for minimal residual disease in colorectal cancer, highlighting the need for novel regimens and surrogate endpoints.

Targeting minimal residual disease (MRD) in colorectal cancer: Therapeutic strategies, clinical trials, and the path toward molecular cure

Discussion

Member takes

Implication

Key Points

Cite This Study

Targeting minimal residual disease (MRD) in colorectal cancer: Therapeutic strategies, clinical trials, and the path toward molecular cure

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider